117 related articles for article (PubMed ID: 31898658)
1. The role of syndecan-1 during endometrial carcinoma progression.
Solmaz OA
J Cancer Res Ther; 2019; 15(6):1265-1269. PubMed ID: 31898658
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical study of Ki-67 and DNA topoisomerase II in human endometrium.
Ito K; Sasano H; Yabuki N; Matsunaga G; Sato S; Kikuchi A; Yajima A; Nagura H
Mod Pathol; 1997 Apr; 10(4):289-94. PubMed ID: 9110289
[TBL] [Abstract][Full Text] [Related]
3. Expression of cyclin D1 in normal, hyperplastic and neoplastic endometrium and its correlation with Ki-67 and clinicopathological variables.
Ozuysal S; Oztürk H; Bilgin T; Filiz G
Arch Gynecol Obstet; 2005 Feb; 271(2):123-6. PubMed ID: 14740230
[TBL] [Abstract][Full Text] [Related]
4. [Expressions of aromatase protein and sex hormone receptor in endometrial lesions].
Ma XX; Zhang SL; Gao S; Lu JM; Dong F
Zhonghua Fu Chan Ke Za Zhi; 2006 Jun; 41(6):395-8. PubMed ID: 16831363
[TBL] [Abstract][Full Text] [Related]
5. Cyclin D1 and Ki-67 expression in normal, hyperplastic and neoplastic endometrium.
Shevra CR; Ghosh A; Kumar M
J Postgrad Med; 2015; 61(1):15-20. PubMed ID: 25511212
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical study of apoptosis-related Bcl-2 protein and its correlation with proliferation indices (Ki67, PCNA), tumor suppressor genes (p53, pRb), the oncogene c-erbB-2, sex steroid hormone receptors and other clinicopathological features, in normal, hyperplastic and neoplastic endometrium.
Mitselou A; Ioachim E; Kitsou E; Vougiouklakis T; Zagorianakou N; Makrydimas G; Stefanaki S; Agnantis NJ
In Vivo; 2003; 17(5):469-77. PubMed ID: 14598611
[TBL] [Abstract][Full Text] [Related]
7. Ki-67 index as an ancillary tool in the differential diagnosis of proliferative endometrial lesions with secretory change.
Gurda GT; Baras AS; Kurman RJ
Int J Gynecol Pathol; 2014 Mar; 33(2):114-9. PubMed ID: 24487464
[TBL] [Abstract][Full Text] [Related]
8. Differential diagnosis of endometrial hyperplasia and carcinoma by computerized image cytometry of cell proliferation, apoptosis and Bcl-2 expression.
Mora LB; Diaz JI; Cantor AB; Nicosia SV
Ann Clin Lab Sci; 1999; 29(4):308-15. PubMed ID: 10528831
[TBL] [Abstract][Full Text] [Related]
9. Glycoprotein CD44 expression in normal, hyperplasic and neoplastic endometrium. An immunohistochemical study including correlations with p53, steroid receptor status and proliferative indices (PCNA, MIB1).
Zagorianakou N; Ioachim E; Mitselou A; Kitsou E; Zagorianakou P; Stefanaki S; Makrydimas G; Agnantis NJ
Eur J Gynaecol Oncol; 2003; 24(6):500-4. PubMed ID: 14658589
[TBL] [Abstract][Full Text] [Related]
10. Significance of syndecan-1 expression in ductal carcinoma in situ of the breast.
Tiemann K; Weigel MT; Alkatout I; Wenners AS; Mundhenke H; Schäfer FW; Bauer M; Schem C; Maass N; Jonat W; Mundhenke C
Anticancer Res; 2014 Jul; 34(7):3607-16. PubMed ID: 24982376
[TBL] [Abstract][Full Text] [Related]
11. Expression of ER, PR, C-erbB-2 and Ki-67 in Endometrial Carcinoma and their Relationships with the Clinicopathological Features.
Yu CG; Jiang XY; Li B; Gan L; Huang JF
Asian Pac J Cancer Prev; 2015; 16(15):6789-94. PubMed ID: 26434913
[TBL] [Abstract][Full Text] [Related]
12. Utility of Ki-67, p53, Bcl-2, and Cox-2 biomarkers for low-grade endometrial cancer and disordered proliferative/benign hyperplastic endometrium by imprint cytology.
Apostolou G; Apostolou N; Biteli M; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2014 Feb; 42(2):134-42. PubMed ID: 23729350
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical analysis of c-myc, c-jun and estrogen receptor in normal, hyperplastic and neoplastic endometrium.
Bircan S; Ensari A; Ozturk S; Erdogan N; Dundar I; Ortac F
Pathol Oncol Res; 2005; 11(1):32-9. PubMed ID: 15800680
[TBL] [Abstract][Full Text] [Related]
14. GLUT-1 Expression in Proliferative Endometrium, Endometrial Hyperplasia, Endometrial Adenocarcinoma and the Relationship Between GLUT-1 Expression and Prognostic Parameters in Endometrial Adenocarcinoma.
Canpolat T; Ersöz C; Uğuz A; Vardar MA; Altintaş A
Turk Patoloji Derg; 2016; 32(3):141-7. PubMed ID: 27562387
[TBL] [Abstract][Full Text] [Related]
15. Maspin expression, subcellular localization and clinicopathological correlation in endometrial hyperplasia and endometrial adenocarcinoma.
Blandamura S; Alessandrini L; Saccardi C; Giacomelli L; Fabris A; Borghero A; Litta P
Histol Histopathol; 2014 Jun; 29(6):777-83. PubMed ID: 24346847
[TBL] [Abstract][Full Text] [Related]
16. Expression of Ki-67 as proliferation biomarker in imprint smears of endometrial carcinoma.
Kosmas K; Stamoulas M; Marouga A; Kavantzas N; Patsouris E; Athanassiadou P
Diagn Cytopathol; 2013 Mar; 41(3):212-7. PubMed ID: 21965052
[TBL] [Abstract][Full Text] [Related]
17. PAX2 and cyclin D1 expression in the distinction between cervical microglandular hyperplasia and endometrial microglandular-like carcinoma: a comparison with p16, vimentin, and Ki67.
Stewart CJ; Crook ML
Int J Gynecol Pathol; 2015 Jan; 34(1):90-100. PubMed ID: 25473758
[TBL] [Abstract][Full Text] [Related]
18. Differential diagnosis between normal endometrium and endometrial hyperplasia with immunostaining cytology using anti-LeY monoclonal antibody.
Arai Y; Nishida M
Int J Gynecol Cancer; 2003; 13(1):42-6. PubMed ID: 12631219
[TBL] [Abstract][Full Text] [Related]
19. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma.
Zheng W; Yi X; Fadare O; Liang SX; Martel M; Schwartz PE; Jiang Z
Am J Surg Pathol; 2008 Feb; 32(2):304-15. PubMed ID: 18223334
[TBL] [Abstract][Full Text] [Related]
20. Heart and Neural Crest Derivatives Expressed Transcript 2 (HAND2): a novel biomarker for the identification of atypical hyperplasia and Type I endometrial carcinoma.
Buell-Gutbrod R; Cavallo A; Lee N; Montag A; Gwin K
Int J Gynecol Pathol; 2015 Jan; 34(1):65-73. PubMed ID: 25473755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
